Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants

Transplantation

Volumn 99, Issue 2, 2015, Pages 288-298

  Leventhal, Joseph R ^a   Elliott, Mary J ^b   Yolcu, Esma S ^b   Bozulic, Larry D ^c   Tollerud, David J ^b,c   Mathew, James M ^a   Konieczna, Iwona ^a   Ison, Michael G ^a   Galvin, John ^a   Mehta, Jayesh ^a   Badder, Mark D ^b   Abecassis, Michael M I ^a   Miller, Joshua ^a   Gallon, Lorenzo ^a   Ildstad, Suzanne T ^b,c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c NuLease Medical Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; T LYMPHOCYTE RECEPTOR; ALLOANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BK VIRUS INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE RECONSTITUTION; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIREMIA; YOUNG ADULT; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMMUNICABLE DISEASE; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; KIDNEY DISEASES; LIVING DONOR; PHASE 2 CLINICAL TRIAL; PROCEDURES; RISK FACTOR; TIME; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHICAGO; COMMUNICABLE DISEASES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KENTUCKY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84922885564     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000605     Document Type: Article

References (47)

1. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306:1891.
2. Green M. Introduction: infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):3.
3. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl JMed. 2003;349:931.
4. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med. 2012;4:124ra28. PMC3610325.
5. Kaufman CL, Colson YL,Wren SM,Watkins SL, Simmons RL, Ildstad ST. Phenotypic characterization of a novel bone-marrow derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood. 1994;84:2436.
6. Fugier-Vivier I, Rezzoug F, Huang Y, et al. Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exp Med. 2005;201:373-383. PMCID: PMC2213023.
7. Rezzoug F, Huang Y, Tanner MK, et al. TNFa is critical to facilitation of hematopoietic stem cell engraftment and function. J Immunol. 2008; 180:49.
8. + plasmacytoid precursor DC induce antigen-specific regulatory T cells that enhance HSC engraftment in vivo. Blood. 2011;117:2494-2505. PMC3062412.
9. Huang Y, Rezzoug F, Chilton PM, Grimes HL, Cramer DE, Ildstad ST. Matching at the MHC Class I K locus is essential for long-term engraftment of purified hematopoietic stem cells: a role for host NK cells in regulating HSC engraftment. Blood. 2004;104:873.
10. Huang Y, Fugier-Vivier I, Miller T, et al. Plasmacytoid precursor dendritic cells from NODmice exhibit impaired function: are they a component of diabetes pathogenesis? Diabetes. 2008;57:2360-2370. PMCID: PMC2518487.
11. Ruedi E, Sykes M, Ildstad ST, et al. Antiviral T cell competence and restriction specificity of mixed allogeneic (P1 + P2 - > P1) irradiation chimeras. Cell Immunol. 1989;121:185.
12. Zinkernagel RM, Callahan GN, Althage A, Cooper S, Klein PA, Klein J. On the thymus in the differentiation of "H-2 self-recognition" by T cells: evidence for dual recognition? J ExpMed. 1978;147:882.
13. Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation. 2013; 95: 169. PMC3531567.
14. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641.
15. Tambur AR, Leventhal JR, Zitzner JR, Walsh RC, Friedewald JJ. The DQ barrier: improving organ allocation equity using HLA-DQ information. Transplantation. 2013;95:635.
16. Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013; 13:179.
17. Theodoropoulos N,Wang E, Penugonda S, et al. BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation. Am J Transplant. 2012;13:197.
18. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44:521.
19. Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant. 2010;16:S48.
20. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358:362.
21. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012;307:283.
22. Levitsky J. Operational tolerance: past lessons and future prospects. Liver Transpl. 2011;17:222.
23. Ramos HC, Reyes J, Abu-Elmagd K, et al.Weaning of immunosuppression in long-term liver transplant recipients. Transplantation. 1995;59:212.
24. Takatsuki M, Uemoto S, Inomata Y, et al.Weaning of immunosuppression in living donor liver transplant recipients. Transplantation. 2001; 72: 449.
25. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant. 2005;5:330.
26. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A. 2007; 104: 15448.
27. Brouard S, Pallier A, Renaudin K, et al. The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases. Am J Transplant. 2012;12:3296.
28. Shapiro R, Zeevi A, Basu A, et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donorspecific antibody. Transplantation. 2008;85:1125.
29. Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI. Using donorspecific antibodies to monitor the need for immunosuppression. Transplantation. 2012;93:1173.
30. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation. 2009;88:568.
31. OzawaM, Rebellato LM, Terasaki PI, et al. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Clin Transplant. 2006: 265.
32. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant. 2004;4:438-443.
33. Colson YL, Christopher K, Glickman J, Taylor KN, Wright R, Perkins DL. Absence of clinical GVHD and the in vivo induction of regulatory T cells following facilitating cell transplantation. Blood. 2004; 104: 3829.
34. Markmann JF, Kawai T. The quest for transplantation tolerance: have we finally sipped from the cup? Sci Transl Med. 2012;4:124fs5.
35. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med. 2000;192:557.
36. Freitas AA, Rocha B. Population biology of lymphocytes: the flight for survival. Annu Rev Immunol. 2000;18:83.
37. HakimFT, Gress RE. Reconstitution of the lymphocyte compartment after lymphocyte depletion: a key issue in clinical immunology. Eur J Immunol. 2005;35:3099.
38. Rufer N, Helg C, Chapuis B, Roosnek E. Human memory Tcells: lessons from stem cell transplantation. Trends Immunol. 2001;22:136.
39. DomenickMA, Ildstad ST. Impact of bone marrow transplantation on type I diabetes. World J Surg. 2001;25:474.
40. Li M, Ikehara S. Autoimmune disease treatment with stem cell transplantation. Genet Syndr Gene Ther. 2013;4.
41. Daikeler T, Hugle T, Farge D, et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant. 2009; 44:27.
42. van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford). 2006;45:1187-1193.
43. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from The European Group For Blood And Marrow Transplantation Working Party On Autoimmune Diseases. Haematologica. 2010;95:284.
44. Van Bekkum DW. Autologous stem cell transplantation for treatment of autoimmune diseases. Stem Cells. 1999;17:172.
45. Su SH, Martel-Laferrière V, Labbé AC, et al. High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1012.
46. Carlson CS. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun. 2013;4:2680.
47. Yousfi Monod M. IMGT/junction analysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J junctions. Bioinformatics. 2004;20(Suppl 1):i379.